Liminatus Pharma, Inc. (LIMNW) — SEC Filings
Liminatus Pharma, Inc. (LIMNW) — 15 SEC filings. Latest: 8-K (Nov 25, 2025). Includes 9 8-K, 3 10-Q, 1 S-1/A.
View Liminatus Pharma, Inc. on SEC EDGAR
Overview
Liminatus Pharma, Inc. (LIMNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 25, 2025: Liminatus Pharma, Inc. filed an 8-K on November 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Iris Parent Holding Corp., is incorporated in Delaware and operates in the biological products sector.
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 6 bearish, 7 neutral, 2 mixed. The dominant filing sentiment for Liminatus Pharma, Inc. is neutral.
Filing Type Overview
Liminatus Pharma, Inc. (LIMNW) has filed 9 8-K, 3 10-Q, 1 S-1/A, 1 S-1, 1 8-K/A with the SEC between May 2025 to Nov 2025.
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of LIMNW's 15 recent filings, 8 were flagged as high-risk, 3 as medium-risk, and 4 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$1.82M |
| Cash Position | $724,502 |
| Total Assets | $1.34M |
| Total Debt | $2.99M |
Key Executives
- Sponsor
- CEO
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing to fund operations and clinical trials. The competitive landscape includes both large, established players and smaller biotech firms, with success often hinging on the ability to bring novel therapies to market and navigate complex regulatory pathways.
Top Tags
Biotechnology (4) · delisting (3) · SEC Filing (3) · compliance (2) · Pre-clinical Stage (2) · 10-Q Filing (2) · regulatory-filing (2) · Financial Risk (2) · financials (2) · acquisition (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $1.82M | Increased from $601,372 in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $2.04M | Improved from $3.32 million in 2024 due to vendor payable forgiveness |
| Cash as of Sept 30, 2025 | $724,502 | Significant increase from $56,319 at Dec 31, 2024 |
| Gross proceeds from PIPE investment | $10.56M | Key source of cash inflow for the nine months ended Sept 30, 2025 |
| Related party debt converted to common stock | $14.80M | Reduced total liabilities significantly post-Business Combination |
| General and administrative expenses for nine months ended Sept 30, 2025 | $2.08M | Increased from $477,542 in the prior year, reflecting higher operational costs |
| Shares of common stock outstanding | 27,064,633 | As of November 13, 2025, reflecting post-merger capitalization |
| Forgiveness of unrelated vendor payables | $2.14M | Contributed to reduced net loss for the nine-month period |
| Loss on exchange of common stock for warrants | $1.74M | Impacted other income (expense) for the three and nine months ended Sept 30, 2025 |
| Total liabilities as of Sept 30, 2025 | $2.99M | Decreased substantially from $24.75 million at Dec 31, 2024 |
| Net income for Q2 2025 | $113,287 | Significant improvement from $(961,207) net loss in Q2 2024 |
| Net loss for H1 2025 | $(214,239) | Reduced from $(2,715,185) net loss in H1 2024 |
| Cash as of June 30, 2025 | $1,338,222 | Increased from $56,319 at December 31, 2024, largely due to PIPE financing |
| Accumulated deficit as of June 30, 2025 | $28,879,455 | Indicates significant historical losses and contributes to going concern doubt |
| Total consideration from PIPE Financing | $15,000,000 | Provided capital, including $10,556,500 in cash proceeds |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Liminatus Pharma, Inc. (LIMNW)?
Liminatus Pharma, Inc. has 15 recent SEC filings from May 2025 to Nov 2025, including 9 8-K, 3 10-Q, 1 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LIMNW filings?
Across 15 filings, the sentiment breakdown is: 6 bearish, 7 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Liminatus Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Liminatus Pharma, Inc. (LIMNW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Liminatus Pharma, Inc.?
Key financial highlights from Liminatus Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LIMNW?
The investment thesis for LIMNW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Liminatus Pharma, Inc.?
Key executives identified across Liminatus Pharma, Inc.'s filings include Sponsor, CEO.
What are the main risk factors for Liminatus Pharma, Inc. stock?
Of LIMNW's 15 assessed filings, 8 were flagged high-risk, 3 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Liminatus Pharma, Inc.?
Forward guidance and predictions for Liminatus Pharma, Inc. are extracted from SEC filings as they are enriched.